January 07, 2021

Theratechnologies Announces Preliminary Fourth Quarter And Full Fiscal Year 2020 Revenues And Provides Update On R&D Activities

Expects record Q4 and FY 2020 revenues

 Receives ‘Study May Proceed’ letters from FDA for Phase 3 trial of tesamorelin in NASH and Phase 1 trial of TH1902 in various cancers

 Montreal, Canada – January 7, 2021 – Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced net revenue estimates for its fourth quarter and its full fiscal year ended November 30, 2020 and provided an update on its R&D activities.

Consolidated net revenues for the Company’s fourth quarter fiscal year 2020 are expected to be between US$18.9 million and US$19.2 million, compared to US$16.4 million for the same quarter last year, representing an increase of approximately 15% to 17%, and the Company’s highest reported quarterly revenues to date.

Consolidated net revenues for the Company’s full fiscal year 2020 are expected to be between US$65.8 million and US$66.1 million, compared to US$63.2 million for the fiscal year ended November 30, 2019, representing an increase of approximately 4.1% to 4.6%, and the Company’s highest reported annual revenues to date.